Atai targets valuation of $2.3 billion in U.S. IPO

CANNANNEW REPORT

Christian & Peter are dreaming big big big… Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, said on Friday it was looking to raise as much as $214.3 million through a U.S. initial public offering, targeting a valuation of about $2.3 billion. The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental health disorders, said it plans to sell around 14.29 million shares priced between $13 and $15 per share.   THE PRESS RELEASE atai Life Sciences Announces Launch of Initial Public Offering BERLIN, June 11, 2021 (GLOBE NEWSWIRE) — atai Life Sciences B.V. (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the commencement of a proposed underwritten initial public offering of 14,286,000 of its common shares. All common shares to be sold in the proposed offering will be sold by atai. The underwriters of the offering will have a 30-day option to purchase up to an additional 2,142,900 common shares at the initial public offering price, less the underwriting discounts and commissions. The initial public offering price is expected to be between $13.00 and $15.00 per common share. atai has applied to list its common shares on the Nasdaq Global Market under the ticker symbol “ATAI.” Credit Suisse, Citigroup, Cowen, and Berenberg are acting as book-running managers for the proposed offering. Cantor, RBC Capital Markets and Canaccord Genuity are also acting as book-running managers for the proposed offering. The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to this offering, when available, may be obtained by contacting Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, or by telephone at (800) 221-1037 or by email at usa.prospectus@credit-suisse.com; Citigroup Global Markets…

Excerpt only …
READ MORE BELOW
Source : Atai targets valuation of .3 billion in U.S. IPO

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.